Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1–Related Cutaneous Neurofibromas
Journal of Investigative Dermatology, ISSN: 0022-202X, Vol: 144, Issue: 9, Page: 2052-2065.e8
2024
- 2Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
- Mentions1
- News Mentions1
- 1
Most Recent News
New Neurofibromatosis Type 1 Data Have Been Reported by Researchers at Van Andel Research Institute (Ex Vivo Patient-derived Explant Model for Neurofibromatosis Type 1-related Cutaneous Neurofibromas)
2024 SEP 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Daily News -- New research on Nervous System
Article Description
Cutaneous neurofibromas (CNFs) are benign tumors that occur in the dermis of individuals with the inherited tumor predisposition disorder, neurofibromatosis type 1. CNFs cause disfigurement, pain, burning, and itching, resulting in substantially reduced QOL in patients with neurofibromatosis type 1. CNFs are benign tumors that exhibit cellular and molecular heterogeneity, making it difficult to develop tractable in vitro or in vivo models. As a result, CNF research and drug discovery efforts have been limited. To address this need, we developed a reproducible patient-derived explant (PDE) ex vivo culture model using CNF tumors from patients with neurofibromatosis type 1. CNF PDEs remain viable in culture for over 9 days and recapitulate the cellular composition and molecular signaling of CNFs. Using CNF PDEs as a model system, we found that proliferation was associated with increased T-cell infiltration. Furthermore, we identified a pattern of reciprocal inflammatory signaling in CNF PDEs in which tumors rely on prostaglandin or leukotriene-mediated signaling pathways. As proof of principle, we show that ex vivo glucocorticoid treatment reduced the expression of proinflammatory genes, confirming that CNF PDEs are a useful model for both mechanistic studies and preclinical drug testing.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022202X24001179; http://dx.doi.org/10.1016/j.jid.2024.01.032; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85187396365&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38395106; https://linkinghub.elsevier.com/retrieve/pii/S0022202X24001179; https://dx.doi.org/10.1016/j.jid.2024.01.032
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know